Cardiovascular Systems, Inc. (CSII)

NASDAQ: CSII · IEX Real-Time Price · USD
15.61
0.87 (5.90%)
May 20, 2022 4:00 PM EDT - Market closed
Market Cap636.66M
Revenue (ttm)244.71M
Net Income (ttm)-32.53M
Shares Out40.79M
EPS (ttm)-0.84
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume443,757
Open14.90
Previous Close14.74
Day's Range14.40 - 15.64
52-Week Range14.12 - 44.57
Beta0.91
AnalystsBuy
Price Target22.95 (+47.0%)
Earnings DateMay 4, 2022

About CSII

Cardiovascular Systems, Inc., a medical device company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products, which are catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Corona...

IndustryHealth Care Equipment & Supplies
IPO DateFeb 26, 2009
CEODavid Martin
Employees780
Stock ExchangeNASDAQ
Ticker SymbolCSII
Full Company Profile

Financial Performance

In 2021, CSII's revenue was $258.97 million, an increase of 9.48% compared to the previous year's $236.55 million. Losses were -$13.42 million, -50.72% less than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for CSII stock is "Buy." The 12-month stock price forecast is 22.95, which is an increase of 47.02% from the latest price.

Price Target
$22.95
(47.02% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Cardiovascular Systems' (CSII) Q3 Earnings Top Estimates

Cardiovascular Systems' (CSII) third-quarter revenues declined year over year due to lower Coronary and peripheral revenues.

2 weeks ago - Zacks Investment Research

Cardiovascular Systems (CSII) Reports Q3 Loss, Lags Revenue Estimates

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 10.71% and 2%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

Cardiovascular Systems, Inc. Reports Fiscal 2022 Third Quarter Financial Results

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients wit...

2 weeks ago - Business Wire

Cardiovascular Systems (CSII) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Cardiovascular Systems (CSII) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 weeks ago - Zacks Investment Research

3 Medical Product Stocks Poised to Beat This Earnings Season

Medical product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how ALC, ZBH and CSII are poised ahead of their earnings releases.

Other symbols:ABTALCISRGZBH
3 weeks ago - Zacks Investment Research

Here's Why You Should Hold on to Cardiovascular Systems (CSII)

Investors are optimistic about Cardiovascular Systems' (CSII) robust international growth and upcoming launches.

1 month ago - Zacks Investment Research

Cardiovascular Systems, Inc. to Host Earnings Conference Call on May 4, 2022

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. TO HOST EARNINGS CONFERENCE CALL ON MAY 4, 2022

1 month ago - Business Wire

Cardiovascular Systems, Inc. to Participate at Two Upcoming Healthcare Conferences

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. TO PARTICIPATE AT TWO UPCOMING HEALTHCARE CONFERENCES

1 month ago - Business Wire

Cardiovascular Systems, Inc. Announces First In-Human Experience With Company's Propel™ Percutaneous Ventricular Assi...

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. ANNOUNCES FIRST IN-HUMAN EXPERIENCE WITH COMPANY'S PROPEL™ PERCUTANEOUS VENTRICULAR ASSIST DEVICE

2 months ago - Business Wire

Cardiovascular Systems' (CSII) Low Procedure Volume Dents Sales

Cardiovascular Systems (CSII) notes that recovery from the Delta variant has been suppressed by the emergence of the highly contagious Omicron variant.

2 months ago - Zacks Investment Research

Cardiovascular Systems (CSII) Finances New DCB Development

Per the terms of the deal, Cardiovascular Systems (CSII) is providing milestone-based financing to CVT for the development of coronary and peripheral DCBs.

2 months ago - Zacks Investment Research

Cardiovascular Systems, Inc. Announces First In-Human Experience With Peripheral Everolimus Drug-Coated Balloon

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. Announces First In-Human Experience With Peripheral Everolimus Drug-Coated Balloon

2 months ago - Business Wire

Cardiovascular Systems, Inc. Appoints Jeffery W. Chambers, M.D.

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. Appoints Jeffery W. Chambers, M.D., as Chief Medical Officer.

2 months ago - Business Wire

3 Moonshot Stocks Insiders Are Buying. What Do They Know?

Biotech stocks aren't a sure thing, but one good sign is insiders buying up shares. These three all offer that enticing feature.

Other symbols:NOTVNVCT
2 months ago - InvestorPlace

Cardiovascular Systems, Inc. Announces Partnership With Innova Vascular, Inc. to Develop Full Line of Thrombectomy De...

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. Announces Partnership With Innova Vascular, Inc. to Develop Full Line of Thrombectomy Devices

2 months ago - Business Wire

Cardiovascular Systems' (CSII) Q2 Earnings Lag Estimates

Cardiovascular Systems (CSII) exhibits a robust performance by its worldwide coronary franchise despite challenging business climate.

3 months ago - Zacks Investment Research

Cardiovascular Systems (CSII) Reports Q2 Loss, Misses Revenue Estimates

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -64.29% and 5.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Cardiovascular Systems, Inc. Reports Fiscal 2022 Second Quarter Financial Results

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2022 SECOND QUARTER FINANCIAL RESULTS

3 months ago - Business Wire

Cardiovascular Systems, Inc. to Participate at SVB Leerink 2022 Global Healthcare Conference

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. TO PARTICIPATE AT SVB LEERINK 2022 GLOBAL HEALTHCARE CONFERENCE

3 months ago - Business Wire

Cardiovascular Systems, OrbusNeich Scores FDA Approval For Scoreflex Scoring Balloon

Cardiovascular Systems Inc (NASDAQ: CSII), along with OrbusNeich Medical Company Ltd, have received FDA PMA approval for OrbusNeich's Scoreflex NC Scoring Percutaneous Transluminal Coronary Angioplasty ...

4 months ago - Benzinga

Cardiovascular Systems, Inc. and OrbusNeich Announce FDA PMA Approval of Scoreflex® Scoring Balloon

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. AND ORBUSNEICH ANNOUNCE FDA PMA APPROVAL OF SCOREFLEX® SCORING BALLOON

4 months ago - Business Wire

Cardiovascular Systems (CSII) Expands Lithotripsy Technology

Cardiovascular Systems (CSII) has developed intravascular lithotripsy systems to treat calcific coronary and peripheral artery diseases.

4 months ago - Zacks Investment Research

Cardiovascular Systems To Develop IVL Technology For Coronary, Peripheral Artery Diseases

Cardiovascular Systems Inc (NASDAQ: CSII) has announced the development of intravascular lithotripsy (IVL) technology for coronary and peripheral artery diseases. Enrolling patients in an investigationa...

4 months ago - Benzinga

Cardiovascular Systems, Inc. Announces Development of Intravascular Lithotripsy Technology for the Treatment of Coron...

ST. PAUL, Minn.--(BUSINESS WIRE)--CSI ANNOUNCES DEVELOPMENT OF INTRAVASCULAR LITHOTRIPSY TECHNOLOGY FOR THE TREATMENT OF CORONARY AND PERIPHERAL ARTERY DISEASES

4 months ago - Business Wire

Cardiovascular Systems (CSII) Coronary Sales Up Amid COVID Woe

Cardiovascular Systems (CSII) continues to experience strong demand for physician training and certification in all international markets.

4 months ago - Zacks Investment Research